BioTuesdays

Soricimed approach to COVID-19 being validated by other researchers

Soricimed Logo

Researchers at Rush University Medical Center in Chicago are developing a new peptide treatment to prevent COVID-19 symptoms that supports the approach being taken by closely-held Soricimed Biopharma.

The peptide treatment at Rush is proving effective in reducing fever, protecting lungs, improving heart function, and reversing cytokine storm – a condition in which an infection triggers the immune system to flood the bloodstream with inflammatory proteins, according to a study published in the Journal of Neuroimmune Pharmacology.

The study said that since the SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) for entering into cells, researchers have designed a hexapeptide corresponding to the ACE2-interacting domain of SARS-CoV-2 to inhibit the binding of virus with ACE-2. After intranasal treatment, the peptide reduced fever, protected lungs, normalized heart function, and enhanced locomotor activities in a mouse model of COVID-19, the study said.

Soricimed is investigating the potential therapeutic role its cancer drug candidate, SOR-C13, in helping relieve or prevent severe immune response to the SARS-CoV-2 virus.

Data from early studies by Soricimed suggest that SOR-C13 could interfere with the interaction of the virus with the ACE2 receptor, and stop the entrance of SARS-CoV-2 into healthy cells resulting in the virus’ inability to reproduce.
SOR-C13 is designed to decrease calcium concentrations inside cancer cells to inhibit calcium-dependent cancer cell proliferation and induce death of tumor cells

Emerging COVID-19 data suggest that calcium plays a role in the development and worsening of the infection. Soricimed believes that SOR-C13 could also help reduce the calcium load of SARS-CoV-2 infected cells, in turn decreasing the intensity of the infection.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.